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returned a questionnaire whereas drug history was available for
175 of these patients. Sixty-seven percent (67%) of respondents
were female, and 60% of all respondents had used cannabis
before. The main indications for cannabis use were chronic pain
(72.5%) and muscle cramp/stiffness (53.0%). Among the
cannabis users, 42.0% suffered from multiple sclerosis and
11.0% were diagnosed with rheumatic diseases. The history of
drug use showed a relatively frequent use of analgesics (36.6%)
and psycholeptics (34.9%). Experiences with previous use of
other cannabis products indicated that concomitant drug use
could be decreased in 40.4% of the patients, remained the same
in 48.6% and increased in 0.9%; in total 10.1% did not use any
concomitant drugs. Most reported side effects of previous
cannabis products were lethargy (42.5%) and dry mouth
(38.1%). CONCLUSIONS: The main indications for prescrip-
tion of medicinal cannabis were chronic pain and muscle
cramp/stiffness; multiple sclerosis was the most frequently
reported disease. The majority of patients had used other
cannabis products before, resulting in a decrease in concomitant
drug use in a substantial number of patients. Legalization did
not cause an excessive increase of cannabis used, most likely to
be explained by the more expensive drugs in the pharmacy com-
pared to coffee shops.
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OBJECTIVES: This paper outlines the current development of
the “fourth hurdle” (i.e. requirement of effectiveness and cost-
effectiveness data for drug coverage policy decisions) in one of
the new European Union member states, describes the needs and
seeks to address some of the most important questions in this
ﬁeld. METHODS: The paper draws on international experiences
and discusses some issues that a given jurisdiction needs to con-
sider prior to introducing the “fourth hurdle” for pharmaceuti-
cals. RESULTS: The “fourth hurdle” is very relevant to the new
member states since many existing drugs are unevaluated and
many new, expensive drugs are becoming available. On the other
hand, the existing resources for health technology assessment,
including economic evaluation, are quite limited. CONCLU-
SIONS: The most important issue seems to be that the imple-
mentation of the “fourth hurdle” needs to be achieved in a way
consistent with the limited resources for health economics analy-
sis in the new member states. Speciﬁcally this means that, in
setting priorities for drugs to be evaluated, additional criteria
need to be applied. In particular, priority should be given to
assessing drugs that have been evaluated in other countries, since
this affords the opportunity to adapt existing studies or models
to the situation of the new European Union member states.
Opportunity exists to learn from experiences and mistakes in
other countries and to ﬁnd ways to make optimal use of evidence
produced elsewhere and processes, which are already thoroughly
tested. Given these restrictions, recommendations will be made
on how to implement results of economic evaluation, using
health economics as a tool to support reimbursement of medi-
cines as a case study.
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OBJECTIVES: In this study, the effects of devolution of subsi-
dies for pharmaceuticals from the state to the regional health
authorities—counties—in Sweden were studied. The aim of the
reform in 1998 was to cut the escalating costs associated with
risk sharing mechanisms on a national level as well as the third
party payer principles. METHODS: The documentation was
studied and the history of development and the current opinions
were analysed from interviews in nine counties, selected based
on their method of devolution. RESULTS: Two main principles
were found: either a population-based responsibility for costs;
family medicine in primary care was responsible for costs of
drugs classiﬁed as “basic” (80%) regardless of prescriber, in
addition hospital departments were responsible for “special
drugs” regardless of prescriber. The other model was a pre-
scriber-based responsibility; each unit of care was responsible for
costs of its own prescribing. CONCLUSIONS: Incentives for
cost containment are strongest in the prescriber-based models.
Integration of drug costs in overall Health Care costs, service to
patients and dialogue between providers are supported by the
population-based models.
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On one hand, direct usage of pharmacoeconomic analyses in
contemporary pharmacy practice seems to be limited, on the
other hand correct communication with patients may beneﬁt
from promotion of rational pharmacotherapy, which stems from
both doctors’ decisions (prescribed drugs) and ﬁnancial abilities
of patients (especially when patient’s co-payment is high).
OBJECTIVES: To investigate the level of awareness among 
pharmacists concerning pharmacoeconomics in general, con-
ducting and application of pharmacoeconomic analyses, activi-
ties focused on proper drug management (out-patient
formularies, drug monitoring utilization systems, prescribing
behaviour), etc. METHODS: Managers of 50 randomly selected
pharmacies in Poland were interviewed. RESULTS: At the
moment, drug costs, experts’ opinion, personal opinion and drug
efﬁcacy are the most important sources of information. However,
in an ideal situation the order should be different: efﬁcacy, expert
opinions and costs. Lack of governmental agencies’ regulations
on pharmacoeconomic evaluations, limited access to standarised
cost data and low reliability of existing results of studies are
listed among the main drawbacks in application of pharma-
coeconomic study results. Wider use of pharmacoeconomics may
be due to the creation of national cost databases in Health Care
and introduction of transparent evaluation criteria. Societal and
patient’s viewpoint were indicated as the most appropriate where
87% of respondents declared the need to expand their knowl-
edge in the ﬁeld, 48% supported the idea of the creation of out-
patient formularies, 42% were opposed, 65% conﬁrmed the
necessity of introduction of central drug usage monitoring
systems, 65% of pharmacists claimed that they should inform
GP’s that their patients are unable to purchase a prescribed drug
(co-payment is too high, need for substitution) and 75% thought
that discussing economic aspects of treatment with patients was
